Repligen Co. (NASDAQ:RGEN) Shares Acquired by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. grew its stake in Repligen Co. (NASDAQ:RGEN) by 937.8% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 30,189 shares of the biotechnology company’s stock after purchasing an additional 27,280 shares during the quarter. Assenagon Asset Management S.A. owned approximately 0.05% of Repligen worth $3,806,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the stock. V Square Quantitative Management LLC raised its stake in shares of Repligen by 23.6% in the 2nd quarter. V Square Quantitative Management LLC now owns 697 shares of the biotechnology company’s stock valued at $88,000 after purchasing an additional 133 shares in the last quarter. Diversified Trust Co grew its position in shares of Repligen by 3.7% during the 2nd quarter. Diversified Trust Co now owns 2,949 shares of the biotechnology company’s stock valued at $372,000 after buying an additional 106 shares during the last quarter. Mather Group LLC. grew its position in shares of Repligen by 2,345.2% during the 2nd quarter. Mather Group LLC. now owns 1,027 shares of the biotechnology company’s stock valued at $129,000 after buying an additional 985 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Repligen by 183.4% during the 2nd quarter. GAMMA Investing LLC now owns 479 shares of the biotechnology company’s stock valued at $60,000 after buying an additional 310 shares during the last quarter. Finally, NBW Capital LLC grew its position in shares of Repligen by 1.7% during the 1st quarter. NBW Capital LLC now owns 33,616 shares of the biotechnology company’s stock valued at $6,183,000 after buying an additional 578 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Stock Performance

RGEN opened at $153.82 on Tuesday. Repligen Co. has a 1-year low of $110.45 and a 1-year high of $211.13. The company has a market capitalization of $8.59 billion, a price-to-earnings ratio of 615.28, a price-to-earnings-growth ratio of 5.72 and a beta of 0.95. The business has a 50 day moving average price of $137.40 and a two-hundred day moving average price of $164.00. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.65 and a quick ratio of 5.56.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share for the quarter, meeting the consensus estimate of $0.33. Repligen had a positive return on equity of 3.36% and a negative net margin of 0.32%. The business had revenue of $154.07 million during the quarter, compared to analysts’ expectations of $154.11 million. During the same quarter last year, the business posted $0.53 earnings per share. The company’s quarterly revenue was down 3.2% on a year-over-year basis. Research analysts predict that Repligen Co. will post 1.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Stephens reaffirmed an “overweight” rating and set a $170.00 price objective on shares of Repligen in a research report on Tuesday, July 30th. Guggenheim assumed coverage on shares of Repligen in a research report on Tuesday, June 18th. They set a “neutral” rating for the company. UBS Group lowered their price objective on shares of Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a research report on Wednesday, July 31st. Royal Bank of Canada restated an “outperform” rating and issued a $190.00 price target on shares of Repligen in a research note on Wednesday, July 31st. Finally, Benchmark reiterated a “hold” rating on shares of Repligen in a research report on Monday, August 5th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $189.57.

Insiders Place Their Bets

In other Repligen news, CEO Anthony Hunt purchased 2,000 shares of the company’s stock in a transaction on Friday, June 14th. The shares were purchased at an average cost of $124.08 per share, for a total transaction of $248,160.00. Following the completion of the transaction, the chief executive officer now owns 165,177 shares in the company, valued at $20,495,162.16. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director Martin D. Madaus acquired 1,615 shares of the business’s stock in a transaction on Friday, June 14th. The shares were purchased at an average price of $124.94 per share, for a total transaction of $201,778.10. Following the acquisition, the director now owns 4,613 shares in the company, valued at $576,348.22. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Anthony Hunt acquired 2,000 shares of the business’s stock in a transaction on Friday, June 14th. The shares were bought at an average price of $124.08 per share, for a total transaction of $248,160.00. Following the acquisition, the chief executive officer now owns 165,177 shares in the company, valued at approximately $20,495,162.16. The disclosure for this purchase can be found here. 1.20% of the stock is owned by company insiders.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.